Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending February 08, 2005. The report serves as a notification of changes in directors' interests in the company's Ordinary Shares.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document focuses exclusively on corporate governance and equity transactions rather than financial performance.
Material Changes
The material changes reported involve the transfer of shares from the GlaxoSmithKline Employee Trust ("the GSK Trust") to plan participants on February 07, 2005:
- 11,996 Ordinary Shares were transferred to participants in the SmithKline Beecham Mid Term Incentive Plan.
- 2,000 Ordinary Shares were transferred to participants in the SmithKline Beecham Employee Share Option Plan 1991.
Outlook, Risks, and Management Commentary
The filing notes that the GSK Trust is a discretionary trust where all current and former employees are potential beneficiaries. Consequently, three directors—Dr J-P Garnier, Dr T Yamada, and Mr J D Coombe—hold an interest in the shares held by the trust in the same manner as other employees. No specific guidance, risks, or unusual items regarding business operations are disclosed in this text.
Key Facts for Investor Verification
- Verify the total number of shares transferred from the GSK Trust (13,996 total) and their allocation between the Mid Term Incentive Plan and the 1991 Share Option Plan.
- Confirm the specific interests of directors Dr J-P Garnier, Dr T Yamada, and Mr J D Coombe in the GSK Trust.
- Note that this filing does not contain financial results; investors should refer to Form 20-F or other periodic reports for financial data.